<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21323" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Esmolol</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pevtsov</surname>
            <given-names>Aleksandr</given-names>
          </name>
          <aff>Southeastern Health- Campbell University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kerndt</surname>
            <given-names>Connor C.</given-names>
          </name>
          <aff>Spectrum Health/Michigan State University College of Human Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ahmed</surname>
            <given-names>Intisar</given-names>
          </name>
          <aff>Aga Khan University Pakistan</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fredlund</surname>
            <given-names>Katherine L.</given-names>
          </name>
          <aff>Campbell University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Aleksandr Pevtsov declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Connor Kerndt declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Intisar Ahmed declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Katherine Fredlund declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21323.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Esmolol, or esmolol hydrochloride, is an intravenous cardioselective &#x003b2;-1 adrenergic antagonist. This drug has received approval from the United States Food and Drug Administration (FDA) for short-term use in managing supraventricular tachycardia, including rapid ventricular rates in individuals with atrial fibrillation or atrial flutter, and hypertension induced by intubation. Esmolol is a valuable emergency medication for focal atrial tachycardia, particularly in individuals experiencing active bronchospasm. Furthermore, esmolol has proven to be a safe and efficient medication for controlling blood pressure during surgery due to its short half-life. The drug is also indicated in cases of sinus tachycardia, where a rapid heartbeat requires immediate intervention, especially in the case of acute coronary syndrome.</p>
        <p>Esmolol is used in various settings, including urgent care, perioperative care, and postoperative care. This drug is used off-label for managing rate and rhythm in conditions such as aortic dissection, acute coronary syndrome, non-ST elevation myocardial infarction, hypertensive emergencies, thyrotoxicosis, refractory ventricular tachycardia, ventricular fibrillation resistant to defibrillation, and for mitigating the catecholamine response during electroconvulsive therapy. This activity focuses on the indications, mechanism of action, adverse events, pharmacology, monitoring, contraindications,&#x000a0;clinical toxicology, and relevant interactions of esmolol. This activity also highlights the crucial role of interprofessional healthcare teams involved in assessing treatment approaches and treating patients with tachycardia and related conditions where esmolol is beneficial, considering individual patient needs and potential risk factors.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the appropriate indications for esmolol use, recognizing scenarios such as supraventricular tachycardia, atrial fibrillation, and hypertensive emergencies.</p></list-item><list-item><p>Differentiate between the various clinical settings where esmolol is applicable, including urgent care, perioperative, and emergencies.</p></list-item><list-item><p>Assess the patient's response to esmolol, monitoring vital signs, cardiac parameters, and any potential adverse events during treatment.</p></list-item><list-item><p>Coordinate with interprofessional healthcare teams to optimize esmolol usage within a comprehensive treatment plan, ensuring seamless integration with other therapeutic modalities and patient-centered care.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21323&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21323">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21323.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Esmolol, or esmolol hydrochloride, is an intravenous cardioselective &#x003b2;-1 adrenergic antagonist.<xref ref-type="bibr" rid="article-21323.r1">[1]</xref>&#x000a0;Esmolol is used in various settings, including urgent care, perioperative care, and postoperative care. In the contemporary era, esmolol has the following indications.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Esmolol has received approval from the United States Food and Drug Administration (FDA) for short-term use in managing supraventricular tachycardia, including rapid ventricular rates in individuals with atrial fibrillation or atrial flutter. Esmolol is a valuable emergency medication for focal atrial tachycardia, particularly in individuals experiencing active bronchospasm.<xref ref-type="bibr" rid="article-21323.r2">[2]</xref>&#x000a0;According to 2019 AHA/ACC/HRS (American College of Cardiology/American Heart Association/Heart Rhythm Society) guidelines, intravenous &#x003b2;-blockers such as esmolol are recommended to slow a rapid ventricular response in patients with AF who do not have heart failure, hemodynamic instability, or bronchospasm.<xref ref-type="bibr" rid="article-21323.r3">[3]</xref>&#x000a0;Similarly, the 2023 AHA/ACC/ACCP/HRS (American Heart Association/American College of Cardiology/American College of Clinical Pharmacy/Heart Rhythm Society) guidelines endorse esmolol in hemodynamically stable atrial fibrillation with rapid ventricular response.<xref ref-type="bibr" rid="article-21323.r4">[4]</xref></p>
        <p>Furthermore, esmolol has proven to be a safe and efficient medication used for controlling blood pressure during surgery due to its short half-life.<xref ref-type="bibr" rid="article-21323.r5">[5]</xref>&#x000a0;The drug&#x000a0;is also indicated in sinus tachycardia, where a rapid heartbeat requires immediate intervention, especially in the case of acute coronary syndrome.<xref ref-type="bibr" rid="article-21323.r6">[6]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Esmolol has various off-label uses, such as&#x000a0;managing rate and rhythm in conditions such as aortic dissection, acute coronary syndrome, non-ST elevation myocardial infarction, hypertensive emergencies, thyrotoxicosis, refractory ventricular tachycardia,&#x000a0;refractory to defibrillation, and ventricular fibrillation.<xref ref-type="bibr" rid="article-21323.r7">[7]</xref>&#x000a0;The drug&#x000a0;is also used for mitigating the catecholamine response during electroconvulsive therapy.<xref ref-type="bibr" rid="article-21323.r8">[8]</xref></p>
        <p>According to a recent study, esmolol may improve survival for patients with refractory ventricular fibrillation (RVF) in prehospital settings.<xref ref-type="bibr" rid="article-21323.r9">[9]</xref>&#x000a0;A topical esmolol formulation is investigated for diabetic foot ulcers and&#x000a0;shows promising results in a phase 3 randomized controlled trial.<xref ref-type="bibr" rid="article-21323.r10">[10]</xref>&#x000a0;The randomized, double-blind, placebo-controlled trial investigated the effectiveness of a single bolus dose of esmolol in attenuating cardiorespiratory responses during extubation, highlighting&#x000a0;the potential as a safe and effective strategy in managing extubation-related complications.<xref ref-type="bibr" rid="article-21323.r11">[11]</xref></p>
        <p><bold>Hypertensive emergency:&#x000a0;</bold>Loading dose of 500 to 1000 mcg/kg over 1 minute (can be repeated once), followed by infusion of 50 mcg/kg/min until the maximum&#x000a0;dose of 200 mcg/kg/min is achieved.<xref ref-type="bibr" rid="article-21323.r12">[12]</xref><xref ref-type="bibr" rid="article-21323.r13">[13]</xref></p>
        <p><bold>Aortic dissection:&#x000a0;</bold>Loading dose of 500 mcg/kg over 2 to 5 minutes, followed by 10 mcg/kg infusion to 20 mcg/kg/min.<xref ref-type="bibr" rid="article-21323.r14">[14]</xref></p>
        <p><bold>Acute coronary syndrome:&#x000a0;</bold>Loading dose of 500 mcg/kg over 1 minute, followed by 50 mcg/kg&#x000a0;per minute&#x000a0;infusion titrated every 5 to 15 minutes until the maximum&#x000a0;dose of 300 mcg/kg/min.<xref ref-type="bibr" rid="article-21323.r15">[15]</xref></p>
        <p><bold>Electroconvulsive therapy:&#x000a0;</bold>Loading dose of 1000 mcg/kg over 1 minute&#x000a0;before administration of anesthesia.<xref ref-type="bibr" rid="article-21323.r16">[16]</xref></p>
        <p><bold>Thyrotoxicosis:&#x000a0;</bold>50 to 100 mcg/kg/min.</p>
        <p><bold>Intubation cholinergic response:&#x000a0;</bold>Loading dose of 1000 to 2000 mcg/kg administered 1.5 to 3 min before endotracheal intubation.</p>
        <p><bold>Ventricular tachycardia, ventricular fibrillation:&#x000a0;</bold>Loading dose of 500 mcg/kg bolus, followed by 50 mcg/kg/min.</p>
      </sec>
      <sec id="article-21323.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Esmolol is a short-acting, cardio-selective &#x003b2;-blocker, a class II antiarrhythmic agent that is a competitive antagonist of the &#x003b2;-1-adrenergic receptors primarily in the myocytes.<xref ref-type="bibr" rid="article-21323.r17">[17]</xref>&#x000a0;By blocking the adrenergic activity of epinephrine and norepinephrine, it decreases contractility (negative inotropic effect), heart rate (negative chronotropic effect), and conduction.<xref ref-type="bibr" rid="article-21323.r18">[18]</xref>&#x000a0;Esmolol increases atrioventricular refractory time, decreases oxygen demand of the myocardium, and decreases atrioventricular conduction (negative dromotropic effect). A minor &#x003b2;-2-adrenergic blockade&#x000a0;is reported with high&#x000a0;IV infusion doses. Esmolol does not have any membrane-stabilizing activity or &#x003b1;-adrenergic blockade.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Esmolol is rapidly absorbed, the onset of action is within 60 seconds, and it maintains a steady state within 5 minutes of initiating infusion.<xref ref-type="bibr" rid="article-21323.r19">[19]</xref>&#x000a0;A steady state&#x000a0;is achieved at 2 minutes if a loading dose is administered. The drug has a 9-minute half-life and rapid renal clearance.</p>
        <p><bold>Distribution:</bold> Esmolol has plasma protein binding of 55%. The mean apparent volume of distribution is approximately 0.33 to 0.53 L/kg.<xref ref-type="bibr" rid="article-21323.r20">[20]</xref></p>
        <p><bold>Metabolism:</bold> Fast metabolism translates into the rapid decrease of pharmacological effect (within 10 to 30 minutes) once the infusion is discontinued, making esmolol safer when titrated appropriately.<xref ref-type="bibr" rid="article-21323.r21">[21]</xref>&#x000a0;Hydrolysis by the erythrocyte esterases metabolizes esmolol to an&#x000a0;acid metabolite and methanol, eliminating&#x000a0;the need for&#x000a0;dose adjustments in renal or hepatic dysfunction.<xref ref-type="bibr" rid="article-21323.r20">[20]</xref></p>
        <p><bold>Elimination:</bold> The metabolite has a half-life of 3.7 hours and is excreted via urine. Esmolol has a higher clearance (281 mL/kg/min) in infants&#x000a0;than in adults&#x000a0;and children.<xref ref-type="bibr" rid="article-21323.r19">[19]</xref></p>
      </sec>
      <sec id="article-21323.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Esmolol&#x000a0;is available in various formulations, including an injection of 100 mg per 10 mL vial (10 mg/mL), a premixed injection bag with 2500 mg in 250 mL (10 mg/mL), and a double-strength premixed injection bag of 2000 mg in 100 mL (20 mg/mL). Esmolol is administered intravenously, preferably through central venous access; however, it can also be infused peripherally.</p>
        <p>FDA approval was based on adult subjects. Pediatric dosages have been experimental and unapproved by the FDA.&#x000a0;Esmolol should be used&#x000a0;short-term, with a maintenance dose infusion under&#x000a0;48 hours. Most patients on esmolol infusions will be transitioned to other long-term agents. Once the effects of esmolol are no longer needed, it should not&#x000a0;be&#x000a0;tapered gradually.<xref ref-type="bibr" rid="article-21323.r6">[6]</xref>&#x000a0;New medication should be initiated, titrating esmolol down by 50% and reassessing hemodynamic stability.&#x000a0;If the patient is stable, continue slowly titrating the esmolol down while titrating the new agent until the desired heart rate and blood pressure are achieved. Peripheral extravasations can cause thrombophlebitis. If the extravasation occurs, the infusion should be stopped, the line should be gently aspirated, and the limb should be elevated.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p><bold>Perioperative and postoperative tachycardia and hypertension (2&#x000a0;</bold><bold>methods):&#x000a0;</bold>A 1000 mcg/kg bolus over 30 seconds, followed by 150 mcg/kg per minute infusion, with a maximum&#x000a0;dose of 300 mcg/kg&#x000a0;per minute.</p>
        <p>A bolus of 500 mcg/kg over 1 minute, followed by 50 mcg/kg/min infusion for 4 minutes. If the desired therapeutic effect is not achieved, the esmolol dose may be increased to 50 mcg/kg/min until the maximum dose of 300 mcg/kg/min.<xref ref-type="bibr" rid="article-21323.r22">[22]</xref></p>
        <p><bold>Supraventricular tachycardia and non-compensatory sinus tachycardia:&#x000a0;</bold>A bolus loading dose of 500 mcg/kg over 1 minute was followed by a 50 mcg/kg/min infusion for 4 minutes. If the desired effect is not reached, it may increase in 50 mcg/kg&#x000a0;per minute&#x000a0;increments until the maximum dose of 200 mcg/kg&#x000a0;per minute. For rapid efficacy, follow the initial loading dose and infusion of 50 mcg/kg&#x000a0;per minute&#x000a0;by a second 500 mcg/kg bolus over 1 minute and increase drip to 100 mcg/kg&#x000a0;per minute&#x000a0;for 4 minutes.<xref ref-type="bibr" rid="article-21323.r23">[23]</xref><bold>&#x000a0;</bold></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment</bold>: Esmolol does not require dosage adjustment for hepatic impairment.<xref ref-type="bibr" rid="article-21323.r24">[24]</xref></p>
        <p><bold>Renal impairment</bold>: Esmolol does not require dosage adjustment for renal&#x000a0;impairment.<xref ref-type="bibr" rid="article-21323.r25">[25]</xref></p>
        <p><bold>Pregnancy considerations</bold>: Esmolol is a category C drug in pregnancy. During trials in third-trimester pregnancy and labor, Esmolol&#x000a0;causes fetal bradycardia, which persisted after the drug infusion was discontinued.<xref ref-type="bibr" rid="article-21323.r26">[26]</xref></p>
        <p><bold>Breastfeeding considerations</bold>:&#x000a0;Esmolol has&#x000a0;55% plasma protein binding, &#x0003c; 1% renal excretion, and a short half-life of &#x0003c;10 minutes; hence, infants have no risk of accumulation. There is inconclusive data regarding milk excretion; however, it should not be used in breastfeeding mothers due to the serious potential for adverse effects.<xref ref-type="bibr" rid="article-21323.r20">[20]</xref><xref ref-type="bibr" rid="article-21323.r27">[27]</xref></p>
        <p><bold>Pediatric patients</bold>: The safety and effectiveness of esmolol&#x000a0;are&#x000a0;unestablished in pediatric patients. However, esmolol is used off-label for supraventricular tachycardia.<xref ref-type="bibr" rid="article-21323.r28">[28]</xref></p>
        <p><bold>Older patients</bold>: The initiation of esmolol dosage in older patients is usually recommended at the lower end of the range&#x000a0;due to a higher prevalence of reduced renal or cardiac function and increased occurrences of concurrent diseases or concomitant drug therapies.</p>
      </sec>
      <sec id="article-21323.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <list list-type="bullet">
          <list-item>
            <p>The most common adverse reaction with esmolol is hemodynamic compromise, which happens to over 10% of all patients.<xref ref-type="bibr" rid="article-21323.r29">[29]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The risk of asymptomatic (25%) and symptomatic (12%) hypotension occurs at all doses, but the risk is dose-dependent.<xref ref-type="bibr" rid="article-21323.r30">[30]</xref>&#x000a0;Hypotension in esmolol patients appears once doses reach 150 mcg/kg&#x000a0;per minute. In clinical trials, esmolol-induced hypotension&#x000a0;is usually corrected by titrating or discontinuing the infusion.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients also experienced dizziness (3%), peripheral ischemia (1%), and infusion site reaction (8%), such as blistering, necrosis, or thrombophlebitis.<xref ref-type="bibr" rid="article-21323.r23">[23]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rare adverse drug reactions (less than 1% of patients without comorbidities) include bradycardia, decompensated heart failure, cardiac arrest, and heart block.<xref ref-type="bibr" rid="article-21323.r31">[31]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Esmolol&#x000a0;does not show any significant laboratory abnormalities, and patients tolerated the drug while being infused for up to 24 hours. However, some cases of hyperkalemia with esmolol use have been reported. Therefore, electrolyte levels should be monitored for hyperkalemia in patients with renal disease.<xref ref-type="bibr" rid="article-21323.r32">[32]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypoglycemic-induced tachycardia is not present with esmolol, like other &#x003b2;-blockers. Patients with diabetes who are on esmolol should be closely monitored. Esmolol&#x000a0;is reported to exacerbate coronary vasospasms, such as Prinzmetal&#x02019;s Angina.<xref ref-type="bibr" rid="article-21323.r33">[33]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In the setting of a patient with pheochromocytoma, esmolol&#x000a0;is given with an &#x003b1;-blocker&#x000a0;to avoid&#x000a0;&#x003b2;-blockage without opposed alpha. Patients with a history of hyperthyroidism should be closely monitored after discontinuation of esmolol as it may exacerbate hyperthyroidism. Esmolol may also aggravate arterial insufficiency in patients with a history of significant peripheral vascular disease.<xref ref-type="bibr" rid="article-21323.r34">[34]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>As the excipient contains methanol, esmolol is&#x000a0;ingested by patients with methanol poisoning.<xref ref-type="bibr" rid="article-21323.r19">[19]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Numerous drug-drug interactions exist with esmolol, the most significant being:</p>
        <list list-type="bullet">
          <list-item>
            <p>Digoxin: A 10% to 20% increase in digoxin levels may aggravate slow AV conduction and heart rate.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Anticholinesterases: Prolonged neuromuscular junction blockage and recovery time.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Calcium channel blockers: Decreases myocardial contractility and may trigger cardiac arrest.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Vasoconstrictor and inotropic agents: Esmolol should not be used to control heart rate elevation in patients who receive peripheral vascular constrictive agents such as epinephrine, norepinephrine, and dopamine.<xref ref-type="bibr" rid="article-21323.r35">[35]</xref><xref ref-type="bibr" rid="article-21323.r36">[36]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21323.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>Esmolol is contraindicated in patients with sinus bradycardia, sick sinus syndrome, atrioventricular heart block, heart failure, cardiogenic shock, pulmonary hypertension, and a history of hypersensitivity reactions to esmolol. In addition, esmolol and calcium channel blockers should not be&#x000a0;administered together, as this may exacerbate hypotension and bradycardia.&#x000a0;Patients with first-degree heart block and nodal dysfunctions are at an increased risk of progressive heart block, bradycardia, and AV dissociation. Patients with preexisting heart failure are at greater risk of decompensated heart failure and cardiogenic shock.<xref ref-type="bibr" rid="article-21323.r37">[37]</xref>&#x000a0;Clinicians should be cautious&#x000a0;when using &#x003b2;-blockers, such as esmolol, in patients with airway diseases such as asthma and COPD. However, the &#x003b2;-2 receptor's effects are minimal; some risks may exist at higher doses.<xref ref-type="bibr" rid="article-21323.r38">[38]</xref></p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p>Esmolol can attenuate reflex tachycardia and increase the risk of hypotension in patients with hypovolemia. Manufacturer labeling suggests that patients using beta blockers may be less responsive to the usual doses of epinephrine used for anaphylactic or anaphylactoid reactions. However, a retrospective observational study examined patients presenting with anaphylaxis in the emergency department and found that 8% required more than one epinephrine dose, and only 13% of those patients were using &#x003b2;-blockers, suggesting no substantial association between &#x003b2;-blocker usage and the need for multiple doses of epinephrine. Overall, the study did not establish a clinically significant link between &#x003b2;-blocker use and the requirement for epinephrine dosing in individuals experiencing anaphylaxis.<xref ref-type="bibr" rid="article-21323.r39">[39]</xref>&#x000a0;The case report documented that the use of esmolol in sterile water was associated with significant hyponatremia and subsequent seizures. Awareness of medication formulations and potential adverse effects is crucial in clinical management.<xref ref-type="bibr" rid="article-21323.r40">[40]</xref></p>
      </sec>
      <sec id="article-21323.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Esmolol is a fast-acting medication that can quickly alter heart rate and pressure.&#x000a0;When the patient is on esmolol, it is recommended that they have continuous blood pressure monitoring, heart rate, mean arterial pressure, and, if possible, ECG.<xref ref-type="bibr" rid="article-21323.r41">[41]</xref>&#x000a0;An arterial line provides the best method of continuous blood pressure monitoring, which is beneficial in use with esmolol.&#x000a0;The peripheral intravenous (IV) site should be checked regularly for any signs or symptoms of infiltration and extravasation.</p>
        <p>As mentioned above, in patients with comorbidities, appropriate serum concentrations, such as glucose (diabetes), thyroid function tests (hyperthyroid), and potassium (renal insufficiency),&#x000a0;are monitored. Peripheral pulses should be checked in patients with peripheral vascular disease.<xref ref-type="bibr" rid="article-21323.r42">[42]</xref>&#x000a0;The CHA2DS2-VASc score&#x000a0;is measured&#x000a0;for&#x000a0;risk stratification of a thromboembolic event and decision regarding anticoagulation according to AHA/ACC guidelines.<xref ref-type="bibr" rid="article-21323.r3">[3]</xref></p>
      </sec>
      <sec id="article-21323.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>An overdose of esmolol can result in a myriad of symptoms and effects. Cardiac signs of toxicity include but are not limited to bradycardia, AV block of any degree, complete AV dissociation, decreased contractility, cardiogenic shock, asystole, and pulseless electrical activity.<xref ref-type="bibr" rid="article-21323.r43">[43]</xref>&#x000a0;Neurologic signs of toxicity include but are not limited to respiratory irregularities, seizures, coma, and psychiatric symptomatology.<xref ref-type="bibr" rid="article-21323.r44">[44]</xref>&#x000a0;Other symptoms of toxicity may include bronchospasms, gastrointestinal mesenteric ischemia, and peripheral cyanosis.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Since esmolol has an ultra-short&#x000a0;half-life, toxicity should be treated by discontinuing the infusion. Acute toxicity is often self-limited and treated supportively. Toxicity that results in bradycardia should be treated by atropine, pacing, and other anticholinergic agents. Cardiogenic shock&#x000a0;is treated with inotropic agents such as dobutamine, dopamine, and isoproterenol. Although rare, bronchospasms&#x000a0;are treated with a &#x003b2;-2 agonist, such as albuterol.<xref ref-type="bibr" rid="article-21323.r45">[45]</xref>&#x000a0;The Advanced Cardiac Life Support protocols should treat pulseless electrical activity and cardiac arrest. As with other &#x003b2;-blocker overdoses, calcium chloride&#x000a0;is given to mitigate the effects of esmolol&#x000a0;when&#x000a0;metabolized. High-dose insulin euglycaemic therapy and&#x000a0;veno-arterial extracorporeal membrane oxygenation&#x000a0;are associated with reduced mortality.<xref ref-type="bibr" rid="article-21323.r46">[46]</xref></p>
      </sec>
      <sec id="article-21323.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Healthcare professionals, including those in the MICU and CCU who administer esmolol, should be familiar with&#x000a0;the adverse effects.&#x000a0;Esmolol is an ultra-fast-acting medication that controls heart rate and pressure. Therefore,&#x000a0;when the patient is on esmolol, it is recommended that nursing staff continuously monitor patients for blood pressure, heart rate, mean arterial pressure, and, if possible, ECG. An arterial line will provide the best continuous blood pressure monitoring method, which is beneficial when used with esmolol. The intravenous site should be checked regularly to prevent infiltration and extravasation. The pharmacist should perform medication reconciliation and inform the prescriber of any concerns.</p>
        <p>Given the pharmacodynamics of esmolol, it is advisable to use an interprofessional team approach to the drug. This interprofessional team includes clinicians, specialists, nurses, and pharmacists, all coordinating their activities and communicating openly so team members are operating from the same information and can intervene or report the need for intervention and achieve optimal patient outcomes related to esmolol therapy.<bold>&#x000a0;</bold>According to the 2016&#x000a0;ESC (European Society of Cardiology),&#x000a0;managing patients with&#x000a0;atrial fibrillation requires&#x000a0;coordination&#x000a0;from an interprofessional team consisting of specialists, stroke clinicians, cardiologists, clinicians, AF surgeons, allied healthcare professionals, patients, and family members and integrated care has the potential to enhance&#x000a0;patient outcomes.<xref ref-type="bibr" rid="article-21323.r47">[47]</xref></p>
      </sec>
      <sec id="article-21323.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21323&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21323">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21323/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21323">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21323.s11">
        <title>References</title>
        <ref id="article-21323.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Flaherty</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Esmolol.</article-title>
            <source>Can J Anaesth</source>
            <year>1993</year>
            <month>Jul</month>
            <volume>40</volume>
            <issue>7</issue>
            <fpage>687</fpage>
            <page-range>687-8</page-range>
            <pub-id pub-id-type="pmid">8104725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Das</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tschida</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dhurandhar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lester</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McGrew</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Askenazi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Emanuele</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turlapaty</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of esmolol in the treatment and transfer of patients with supraventricular tachyarrhythmias to alternate oral antiarrhythmic agents.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1988</year>
            <month>Aug</month>
            <volume>28</volume>
            <issue>8</issue>
            <fpage>746</fpage>
            <page-range>746-50</page-range>
            <pub-id pub-id-type="pmid">2905710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>January</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Wann</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Calkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Cigarroa</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Cleveland</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ellinor</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ezekowitz</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Furie</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Shea</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.</article-title>
            <source>Circulation</source>
            <year>2019</year>
            <month>Jul</month>
            <day>09</day>
            <volume>140</volume>
            <issue>2</issue>
            <fpage>e125</fpage>
            <page-range>e125-e151</page-range>
            <pub-id pub-id-type="pmid">30686041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Writing Committee Members</collab>
              <name>
                <surname>Joglar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Armbruster</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Chyou</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Cronin</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eckhardt</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Goldberger</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Gopinathannair</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gorenek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Hlatky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hogan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ibeh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Indik</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kido</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kusumoto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Linta</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Patton</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Piccini</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Streur</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Times</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tisdale</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Van Wagoner</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint&#x000a0;Committee&#x000a0;on&#x000a0;Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2024</year>
            <month>Jan</month>
            <day>02</day>
            <volume>83</volume>
            <issue>1</issue>
            <fpage>109</fpage>
            <page-range>109-279</page-range>
            <pub-id pub-id-type="pmid">38043043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gray</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Bateman</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Czer</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Conklin</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Matloff</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>1985</year>
            <month>Jun</month>
            <volume>5</volume>
            <issue>6</issue>
            <fpage>1451</fpage>
            <page-range>1451-6</page-range>
            <pub-id pub-id-type="pmid">2860148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garnock-Jones</surname>
                <given-names>KP</given-names>
              </name>
            </person-group>
            <article-title>Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension.</article-title>
            <source>Drugs</source>
            <year>2012</year>
            <month>Jan</month>
            <day>01</day>
            <volume>72</volume>
            <issue>1</issue>
            <fpage>109</fpage>
            <page-range>109-32</page-range>
            <pub-id pub-id-type="pmid">22191799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sung</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Blanski</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kirshenbaum</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>MacCosbe</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Turlapaty</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Laddu</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1986</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>S1</issue>
            <fpage>A15</fpage>
            <page-range>A15-A26</page-range>
            <pub-id pub-id-type="pmid">2870082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aydogan</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Y&#x000fc;cel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Begec</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Colak</surname>
                <given-names>YZ</given-names>
              </name>
              <name>
                <surname>Durmus</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The hemodynamic effects of dexmedetomidine and esmolol in electroconvulsive therapy: a retrospective comparison.</article-title>
            <source>J ECT</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>308</fpage>
            <page-range>308-11</page-range>
            <pub-id pub-id-type="pmid">23774056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patrick</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Crowe</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mohammed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Keene</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Feasibility of prehospital esmolol for refractory ventricular fibrillation.</article-title>
            <source>J Am Coll Emerg Physicians Open</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>e12700</fpage>
            <pub-id pub-id-type="pmid">35425942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rastogi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kulkarni</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Akhtar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arsule</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhamre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhosle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Deshmukh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giriraja</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Jagannath</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kashiva</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Kesavan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Khandelwal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kolte</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kongara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Darivemula</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Madhusudan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pyare Saheb Qureshi</surname>
                <given-names>MAH</given-names>
              </name>
              <name>
                <surname>Ramu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rathod</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yalamanchi</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Shakya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shetty</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Deshpande</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Viswanathan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Unnikrishnan</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Topical Esmolol Hydrochloride as a Novel Treatment Modality for Diabetic Foot Ulcers: A Phase 3 Randomized Clinical Trial.</article-title>
            <source>JAMA Netw Open</source>
            <year>2023</year>
            <month>May</month>
            <day>01</day>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>e2311509</fpage>
            <pub-id pub-id-type="pmid">37184839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mendon A</surname>
                <given-names>F&#x000cd;T</given-names>
              </name>
              <name>
                <surname>Barreto Filho</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hungria</surname>
                <given-names>MBCS</given-names>
              </name>
              <name>
                <surname>Magalh Es</surname>
                <given-names>TC</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of a single dose of esmolol to prevent extubation-related complications during emergence from anesthesia: a randomized, double-blind, placebo-controlled trial.</article-title>
            <source>Braz J Anesthesiol</source>
            <year>2023</year>
            <season>Jul-Aug</season>
            <volume>73</volume>
            <issue>4</issue>
            <fpage>426</fpage>
            <page-range>426-433</page-range>
            <pub-id pub-id-type="pmid">34560115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rhoney</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>WF</given-names>
              </name>
            </person-group>
            <article-title>Intravenous therapy for hypertensive emergencies, part 2.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2009</year>
            <month>Aug</month>
            <day>15</day>
            <volume>66</volume>
            <issue>16</issue>
            <fpage>1448</fpage>
            <page-range>1448-57</page-range>
            <pub-id pub-id-type="pmid">19667001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <chapter-title>Esmolol</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>1</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">31644101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krenz</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of esmolol for heart rate control in patients with acute aortic dissection.</article-title>
            <source>Am J Emerg Med</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>44</volume>
            <fpage>312</fpage>
            <page-range>312-314</page-range>
            <pub-id pub-id-type="pmid">32354528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kloner</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Kirshenbaum</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Antman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Experimental and clinical observations on the efficacy of esmolol in myocardial ischemia.</article-title>
            <source>Am J Cardiol</source>
            <year>1985</year>
            <month>Oct</month>
            <day>23</day>
            <volume>56</volume>
            <issue>11</issue>
            <fpage>40F</fpage>
            <page-range>40F-48F</page-range>
            <pub-id pub-id-type="pmid">2864848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howie</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Hiestand</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Zvara</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>McSweeney</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Coffman</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Defining the dose range for esmolol used in electroconvulsive therapy hemodynamic attenuation.</article-title>
            <source>Anesth Analg</source>
            <year>1992</year>
            <month>Nov</month>
            <volume>75</volume>
            <issue>5</issue>
            <fpage>805</fpage>
            <page-range>805-10</page-range>
            <pub-id pub-id-type="pmid">1358003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>do Vale</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Ceron</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Gonzaga</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Simplicio</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Padovan</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Three Generations of &#x003b2;-blockers: History, Class Differences and Clinical Applicability.</article-title>
            <source>Curr Hypertens Rev</source>
            <year>2019</year>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-31</page-range>
            <pub-id pub-id-type="pmid">30227820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agrios</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kaladaridou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bramos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Skaltsiotes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pamboucas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Papadopoulou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Toumanidis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moulopoulos</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The acute effects of esmolol on left ventricular hemodynamic, rotational mechanics and strain in intact and infracted myocardium: An experimental study.</article-title>
            <source>Hellenic J Cardiol</source>
            <year>2021</year>
            <season>Jul-Aug</season>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>322</fpage>
            <page-range>322-323</page-range>
            <pub-id pub-id-type="pmid">32800920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiest</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Haney</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics and therapeutic efficacy of esmolol.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2012</year>
            <month>Jun</month>
            <day>01</day>
            <volume>51</volume>
            <issue>6</issue>
            <fpage>347</fpage>
            <page-range>347-56</page-range>
            <pub-id pub-id-type="pmid">22515557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r20">
          <label>20</label>
          <element-citation publication-type="book">
            <chapter-title>Esmolol</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Covinsky</surname>
                <given-names>JO</given-names>
              </name>
            </person-group>
            <article-title>Esmolol: a novel cardioselective, titratable, intravenous beta-blocker with ultrashort half-life.</article-title>
            <source>Drug Intell Clin Pharm</source>
            <year>1987</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>316</fpage>
            <page-range>316-21</page-range>
            <pub-id pub-id-type="pmid">2882993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poveda-Jaramillo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Monaco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zangrillo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Landoni</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Ultra-Short-Acting &#x003b2;-Blockers (Esmolol and Landiolol) in the Perioperative Period and in Critically Ill Patients.</article-title>
            <source>J Cardiothorac Vasc Anesth</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>1415</fpage>
            <page-range>1415-1425</page-range>
            <pub-id pub-id-type="pmid">29398384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiest</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1995</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>190</fpage>
            <page-range>190-202</page-range>
            <pub-id pub-id-type="pmid">7758250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buchi</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Rollins</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Tolman</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Achari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Drissel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hulse</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of esmolol in hepatic disease.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1987</year>
            <month>Nov</month>
            <volume>27</volume>
            <issue>11</issue>
            <fpage>880</fpage>
            <page-range>880-4</page-range>
            <pub-id pub-id-type="pmid">3323260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flaherty</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>La Follette</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Warnock</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Hulse</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Gambertoglio</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of esmolol and ASL-8123 in renal failure.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1989</year>
            <month>Mar</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>321</fpage>
            <page-range>321-7</page-range>
            <pub-id pub-id-type="pmid">2563962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Regitz-Zagrosek</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Roos-Hesselink</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Bauersachs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blomstr&#x000f6;m-Lundqvist</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>C&#x000ed;fkov&#x000e1;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>De Bonis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iung</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kintscher</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kranke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Morais</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pieper</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Presbitero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosano</surname>
                <given-names>GMC</given-names>
              </name>
              <name>
                <surname>Seeland</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Simoncini</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Swan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Warnes</surname>
                <given-names>CA</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.</article-title>
            <source>Eur Heart J</source>
            <year>2018</year>
            <month>Sep</month>
            <day>07</day>
            <volume>39</volume>
            <issue>34</issue>
            <fpage>3165</fpage>
            <page-range>3165-3241</page-range>
            <pub-id pub-id-type="pmid">30165544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ostman</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Chestnut</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Robillard</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Hdez</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Transplacental passage and hemodynamic effects of esmolol in the gravid ewe.</article-title>
            <source>Anesthesiology</source>
            <year>1988</year>
            <month>Nov</month>
            <volume>69</volume>
            <issue>5</issue>
            <fpage>738</fpage>
            <page-range>738-41</page-range>
            <pub-id pub-id-type="pmid">2903702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oeffl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schober</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Faudon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schweintzger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Manninger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>K&#x000f6;stenberger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sallmon</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Scherr</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kurath-Koller</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Antiarrhythmic Drug Dosing in Children-Review of the Literature.</article-title>
            <source>Children (Basel)</source>
            <year>2023</year>
            <month>May</month>
            <day>08</day>
            <volume>10</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">37238395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Tait</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Karkouti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wijeysundera</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McCluskey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beattie</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>The safety of perioperative esmolol: a systematic review and meta-analysis of randomized controlled trials.</article-title>
            <source>Anesth Analg</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>112</volume>
            <issue>2</issue>
            <fpage>267</fpage>
            <page-range>267-81</page-range>
            <pub-id pub-id-type="pmid">21127279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Byrd</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Sung</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Parmley</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of esmolol (ASL-8052: an ultrashort-acting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardias.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>1984</year>
            <month>Feb</month>
            <volume>3</volume>
            <issue>2 Pt 1</issue>
            <fpage>394</fpage>
            <page-range>394-9</page-range>
            <pub-id pub-id-type="pmid">6141193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r31">
          <label>31</label>
          <element-citation publication-type="book">
            <chapter-title>Beta Adrenergic Blocking Agents</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>6</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">31643457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cork</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Dreischmeier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Behr</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>DiNardo</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>The effect of esmolol given during cardiopulmonary bypass.</article-title>
            <source>Anesth Analg</source>
            <year>1995</year>
            <month>Jan</month>
            <volume>80</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <page-range>28-40</page-range>
            <pub-id pub-id-type="pmid">7802296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pham</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Addison</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kayani</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Misra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jneid</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Resar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lakkis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Alam</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Outcomes of beta blocker use in cocaine-associated chest pain: a meta-analysis.</article-title>
            <source>Emerg Med J</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>9</issue>
            <fpage>559</fpage>
            <page-range>559-563</page-range>
            <pub-id pub-id-type="pmid">29921621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Askenazi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>MacCosbe</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Hoff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Turlapaty</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hua</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Laddu</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Hemodynamic effects of esmolol, an ultrashort-acting beta blocker.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1987</year>
            <month>Aug</month>
            <volume>27</volume>
            <issue>8</issue>
            <fpage>567</fpage>
            <page-range>567-73</page-range>
            <pub-id pub-id-type="pmid">2888793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lowenthal</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Achari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Turlapaty</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Laddu</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Matier</surname>
                <given-names>WL</given-names>
              </name>
            </person-group>
            <article-title>Esmolol-digoxin drug interaction.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1987</year>
            <month>Aug</month>
            <volume>27</volume>
            <issue>8</issue>
            <fpage>561</fpage>
            <page-range>561-6</page-range>
            <pub-id pub-id-type="pmid">2888792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Neuromuscular interactions between mivacurium and esmolol in rabbits.</article-title>
            <source>Anaesthesia</source>
            <year>1998</year>
            <month>Feb</month>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>140</fpage>
            <page-range>140-5</page-range>
            <pub-id pub-id-type="pmid">9534636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bensky</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Donahue-Spencer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hertz</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The dose-related effects of bolus esmolol on heart rate and blood pressure following laryngoscopy and intubation.</article-title>
            <source>AANA J</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>68</volume>
            <issue>5</issue>
            <fpage>437</fpage>
            <page-range>437-42</page-range>
            <pub-id pub-id-type="pmid">11759128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheppard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>DiStefano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Byrd</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Eschenbacher</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Steck</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Laddu</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Effects of esmolol on airway function in patients with asthma.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1986</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>169</fpage>
            <page-range>169-74</page-range>
            <pub-id pub-id-type="pmid">2870080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Greger</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kahoud</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Lohse</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Patients Taking &#x003b2;-Blockers Do Not Require Increased Doses of Epinephrine for Anaphylaxis.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2018</year>
            <season>Sep-Oct</season>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>1553</fpage>
            <page-range>1553-1558.e1</page-range>
            <pub-id pub-id-type="pmid">29449164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zavala</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaminsky</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Roels</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Precipitation of hyponatremia and seizures by esmolol in sterile water formulation.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2024</year>
            <month>Jan</month>
            <day>01</day>
            <volume>81</volume>
            <issue>1</issue>
            <fpage>e18</fpage>
            <page-range>e18-e20</page-range>
            <pub-id pub-id-type="pmid">37787750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jingyi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Xiaogan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weihua</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Xiaoju</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Effect of esmolol on fluid responsiveness and hemodynamic parameters in patients with septic shock].</article-title>
            <source>Zhonghua Wei Zhong Bing Ji Jiu Yi Xue</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>27</volume>
            <issue>11</issue>
            <fpage>885</fpage>
            <page-range>885-9</page-range>
            <pub-id pub-id-type="pmid">27132454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barbier</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Shettigar</surname>
                <given-names>UR</given-names>
              </name>
              <name>
                <surname>Appunn</surname>
                <given-names>DO</given-names>
              </name>
            </person-group>
            <article-title>Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.</article-title>
            <source>Int J Clin Pharmacol Ther</source>
            <year>1995</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>212</fpage>
            <page-range>212-8</page-range>
            <pub-id pub-id-type="pmid">7620691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Litman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Zerngast</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Cardiac arrest after esmolol administration: a review of acute beta-blocker toxicity.</article-title>
            <source>J Am Osteopath Assoc</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>96</volume>
            <issue>10</issue>
            <fpage>616</fpage>
            <page-range>616-8</page-range>
            <pub-id pub-id-type="pmid">8936932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kapitein</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Biesmans</surname>
                <given-names>RCG</given-names>
              </name>
              <name>
                <surname>van der Sijs</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>de Wildt</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>Propylene Glycol-Related Delirium After Esmolol Infusion.</article-title>
            <source>Ann Pharmacother</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>48</volume>
            <issue>7</issue>
            <fpage>940</fpage>
            <page-range>940-942</page-range>
            <pub-id pub-id-type="pmid">24687543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>KO</given-names>
              </name>
            </person-group>
            <article-title>Bronchospasm after esmolol and neostigmine.</article-title>
            <source>Anaesth Intensive Care</source>
            <year>1993</year>
            <month>Aug</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>457</fpage>
            <page-range>457-9</page-range>
            <pub-id pub-id-type="pmid">8105719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rotella</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Koutsogiannis</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Graudins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hung Leang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kuan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Baxter</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bourke</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Treatment for beta-blocker poisoning: a systematic review.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>58</volume>
            <issue>10</issue>
            <fpage>943</fpage>
            <page-range>943-983</page-range>
            <pub-id pub-id-type="pmid">32310006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21323.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirchhof</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Integrated care of patients with atrial fibrillation: the 2016 ESC atrial fibrillation guidelines.</article-title>
            <source>Heart</source>
            <year>2017</year>
            <month>May</month>
            <volume>103</volume>
            <issue>10</issue>
            <fpage>729</fpage>
            <page-range>729-731</page-range>
            <pub-id pub-id-type="pmid">28077464</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
